Remus Pharmaceuticals Limited Stock

Equities

REMUS

INE0O5T01011

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-05-09 am EDT 5-day change 1st Jan Change
7,204 INR -3.08% Intraday chart for Remus Pharmaceuticals Limited -7.07% -5.88%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 247M 2.96M Sales 2023 451M 5.41M Capitalization 10.94B 131M
Net income 2022 33M 396K Net income 2023 85M 1.02M EV / Sales 2022 * -
Net cash position 2022 * - 0 Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 38
Yield 2022 *
-
Yield 2023 *
-
Free-Float 35.76%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.08%
1 week-7.07%
Current month-2.24%
1 month+19.88%
3 months-1.09%
6 months+34.36%
Current year-5.88%
More quotes
1 week
7 150.00
Extreme 7150
8 180.00
1 month
5 650.00
Extreme 5650
8 747.00
Current year
4 800.00
Extreme 4800
8 747.00
1 year
1 711.25
Extreme 1711.25
8 747.00
3 years
1 711.25
Extreme 1711.25
8 747.00
5 years
1 711.25
Extreme 1711.25
8 747.00
10 years
1 711.25
Extreme 1711.25
8 747.00
More quotes
Remus Pharmaceuticals Limited is an India-based company that is engaged in the marketing and distribution of finished formulations of pharmaceutical drugs. It also deals in active pharmaceutical ingredients (API). The Company also provides technical consulting services to various distributors for the preparation of reports on the dossiers of the products. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, and tablet. The Company’s business verticals include the sale of finished formulations, the sale of APIs, and technical consulting. Its product portfolio comprises a range of therapeutic drugs, namely ACE inhibitors, analgesics, anti-erectile dysfunction, anti-fibrinolytics, anti-histamines, beta blockers, carcinoid tumors, chronic obstructive pulmonary disease, and contrast reagents, among others.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW